



PRESS RELEASE

Berlin, 26 June 2017

Organobalance will present results on probiotics at the 2017 ISAPP conference
Conference of International Scientific Association for Probiotics and Prebiotics will be held in Chicago from June 27 to 29

Incidence rates of so-called lifestyle diseases are on the increase due to changes in dietary and lifestyle habits of the general population. Emerging evidence is pointing to a role of the gut microbiome in the low-grade chronic inflammation state common to these metabolic disorders pointing to a potential benefit from supplementation by beneficial bacteria.

In the context of the GOBI (Good Bacteria and Bioactives in Industry) strategic alliance entered into with Evonik Nutrition & Care GmbH and Bionorica SE, researchers from Organobalance are examining an extensive strain collection of lactic acid bacteria to find strains with potential beneficial properties. GOBI was set up in 2016 as a six-year project. First results are now presented at the international ISAPP conference.

Researchers started out by testing the anti-inflammatory properties of bacterial strains. In addition, strains from Organobalance's proprietary collection were analysed in a laboratory model for their ability to strengthen the intestinal mucosa. Currently, the possible modes of action of these strains are being characterised in pre-clinical studies.

Organobalance became part of the Danish biotechnology company Novozymes in 2016. Novozymes became an ISAPP member this year.

About Organobalance:

Organobalance GmbH is a biotechnology research and development company with facilities in Berlin and Flensburg. Founded in 2001, the firm develops and markets products based on probiotic bacteria cultures as well as yeast production strains for use in industrial biotechnology. One of its best-known products is Pylopass™, a natural lactobacillus agent able to bind Helicobacter pylori, a stomach bacterium. Among the company's German and international customers are clients from the food, cosmetics, feed, agriculture, and pharmaceutical industries. The company owns an extensive collection of yeast and lactobacillus cultures, some of which date back to the 1920s. Christine Lang, the company's Managing Director, is also a Professor of Microbiology and Molecular Genetics at the TU Berlin and has received several business awards. She also chairs the German Bioeconomy Council. Since September 2016, Organobalance has become a part of the Danish company Novozymes A/S.

ORGANO BALANCE GMBH
GUSTAV-MEYER-ALLEE 25, GEB. 12
13355 BERLIN, GERMANY
TEL. +49 30 46307-200 • FAX -210

INFO@ORGANOBALANCE.COM
WWW.ORGANOBALANCE.COM
GESCHÄFTSFÜHRERIN: PROF. DR. CHRISTINE LANG
AMTGERICHT CHARLOTTENBURG • HRB 82025

BERLINER VOLKSBANK
BLZ 100 900 00 • KTO. NR. 1 034 9480 00
IBAN: DE72 1009 0000 1034 9480 00
(BIC) SWIFT: BEVODE33

DANSKE BANK A/S
Zweigniederlassung Hamburg
KTO. NR. 4 989 1890 26
IBAN: DE 40 2032 0500 4989 1890 26
(BIC) SWIFT: DABADE



For further information:
ORGANOBALANCE GmbH
Gustav-Meyer-Allee 25
13355 Berlin, Germany
Fon +49 (0) 30 46307 200
Fax +49 (0) 30 46307 210
www.organobalance.com

ORGANOBALANCE GMBH
GUSTAV-MEYER-ALLEE 25, GEB. 12
13355 BERLIN, GERMANY
TEL. +49 30 46307-200 • FAX -210

INFO@ORGANOBALANCE.COM
WWW.ORGANOBALANCE.COM
GESCHÄFTSFÜHRERIN: PROF. DR. CHRISTINE LANG
AMTGERICHT CHARLOTTENBURG • HRB 82025

BERLINER VOLKSBANK
BLZ 100 900 00 • KTO. NR. 1 034 9480 00
IBAN: DE72 1009 0000 1034 9480 00
(BIC) SWIFT: BEVODEBB

DANSKE BANK A/S
Zweigniederlassung Hamburg
KTO. NR. 4 989 1890 26
IBAN: DE 40 2032 0500 4989 1890 26
(BIC) SWIFT: DABADE